A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
The development of immune checkpoint inhibitors (ICI) has revolutionized cancer treatment. ICI stimulates the immune system to recognize and destroys cancer cells via immune checkpoint proteins. However, these drugs can also induce immune-related adverse events (irAE) in off-target organs, such as the heart. The most common manifestation of heart damage is myocarditis, and these rear off-target effects can be life-threatening. Existing data indicate that ICI induces miss-target effects throughdoi:10.3971/j.issn.1000-8578.2018.18.1397 doaj:0ceb8e50ed844a8f93678bd4b2fee050 fatcat:5dj4yto6pncwrgvtsq2bufvlgq